1. Home
  2. GAB vs NTLA Comparison

GAB vs NTLA Comparison

Compare GAB & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GAB
  • NTLA
  • Stock Information
  • Founded
  • GAB 1986
  • NTLA 2014
  • Country
  • GAB United States
  • NTLA United States
  • Employees
  • GAB N/A
  • NTLA N/A
  • Industry
  • GAB Investment Managers
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • GAB Finance
  • NTLA Health Care
  • Exchange
  • GAB Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • GAB 1.6B
  • NTLA 1.5B
  • IPO Year
  • GAB N/A
  • NTLA 2016
  • Fundamental
  • Price
  • GAB $5.70
  • NTLA $14.30
  • Analyst Decision
  • GAB
  • NTLA Buy
  • Analyst Count
  • GAB 0
  • NTLA 17
  • Target Price
  • GAB N/A
  • NTLA $56.63
  • AVG Volume (30 Days)
  • GAB 667.8K
  • NTLA 3.1M
  • Earning Date
  • GAB 01-01-0001
  • NTLA 11-07-2024
  • Dividend Yield
  • GAB 10.91%
  • NTLA N/A
  • EPS Growth
  • GAB N/A
  • NTLA N/A
  • EPS
  • GAB N/A
  • NTLA N/A
  • Revenue
  • GAB N/A
  • NTLA $43,086,000.00
  • Revenue This Year
  • GAB N/A
  • NTLA $50.73
  • Revenue Next Year
  • GAB N/A
  • NTLA $8.69
  • P/E Ratio
  • GAB N/A
  • NTLA N/A
  • Revenue Growth
  • GAB N/A
  • NTLA N/A
  • 52 Week Low
  • GAB $4.56
  • NTLA $12.82
  • 52 Week High
  • GAB $5.88
  • NTLA $34.87
  • Technical
  • Relative Strength Index (RSI)
  • GAB 68.33
  • NTLA 39.75
  • Support Level
  • GAB $5.33
  • NTLA $12.82
  • Resistance Level
  • GAB $5.57
  • NTLA $17.30
  • Average True Range (ATR)
  • GAB 0.06
  • NTLA 1.13
  • MACD
  • GAB 0.01
  • NTLA -0.05
  • Stochastic Oscillator
  • GAB 100.00
  • NTLA 29.54

About GAB Gabelli Equity Trust Inc. (The)

Gabelli Equity Trust Inc is a non-diversified closed-end management investment company. Its primary investment objective is the long-term growth of capital with income as a secondary objective. The Fund invests at least its assets in equity securities under normal market conditions. Its equity portfolio includes common stock, preferred stock, convertible or exchangeable securities, and warrants and rights to purchase such securities selected by the Investment Adviser. The company invests in various sectors, of which Food & Beverage, Financial Services, Equipment and Supplies, Entertainment, Consumer Products, Health Care, Diversified Industrial, Business Services, Consumer Services and others.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: